As of close of business last night, Fate Therapeutics Inc’s stock clocked out at $7.08, down -8.53% from its previous closing price of $7.74. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 1609105 shares were traded.
Ratios:
To gain a deeper understanding of FATE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.
On January 24, 2023, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $115 to $7.
Wedbush Downgraded its Outperform to Neutral on January 06, 2023, whereas the target price for the stock was revised from $42 to $7.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 29 when Dulac Edward J III sold 1,849 shares for $5.00 per share. The transaction valued at 9,245 led to the insider holds 103,926 shares of the business.
Wolchko J Scott sold 14,391 shares of FATE for $62,889 on Jan 09. The President and CEO now owns 371,248 shares after completing the transaction at $4.37 per share. On Jan 09, another insider, Valamehr Bahram, who serves as the Chief R&D Officer of the company, sold 11,271 shares for $4.38 each. As a result, the insider received 49,367 and left with 158,069 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 768.10M and an Enterprise Value of 556.46M. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.06 while its Price-to-Book (P/B) ratio in mrq is 1.90. Its current Enterprise Value per Revenue stands at 8.76 whereas that against EBITDA is -3.23.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $8.63, while it has fallen to a 52-week low of $1.63. The 50-Day Moving Average of the stock is 5.31, while the 200-Day Moving Average is calculated to be 3.81.
Shares Statistics:
It appears that FATE traded 2.64M shares on average per day over the past three months and 2.47M shares per day over the past ten days. A total of 98.63M shares are outstanding, with a floating share count of 86.66M. Insiders hold about 12.68% of the company’s shares, while institutions hold 103.89% stake in the company. Shares short for FATE as of Feb 15, 2024 were 13.31M with a Short Ratio of 5.04, compared to 10.77M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.50% and a Short% of Float of 17.30%.
Earnings Estimates
As of right now, 20 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.48 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.67, while EPS last year was -$0.19. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.29 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$1.4 and -$2.62 for the fiscal current year, implying an average EPS of -$1.94. EPS for the following year is -$1.76, with 17 analysts recommending between -$0.89 and -$2.43.
